Belgium (BE)

Physical literacy in Europe: The current state of implementation in research, practice, and policy (2023) Carl J, Bryant A, Edwards L, Bartle G, Birch J, Christodoulides E, Emeljanovas A, et al. Journal article Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial (2023) Lorusso D, Mouret-Reynier MA, Harter P, Cropet C, Caballero C, Wolfrum-Ristau P, Satoh T, et al. Journal article Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial (2023) Koch R, Haveman L, Ladenstein R, Brichard B, Jürgens H, Cyprova S, van den Berg H, et al. Journal article Joint Offloading Policy and Resource Allocation in IRS-aided MEC for IoT Users with Short Packet Transmission (2023) Jalali J, Khalili A, Berkvens R, Famaey J Conference contribution A Critical Analysis of the Visual Notation for Team Design Patterns (2023) Fleiner C, Zvekan G, Hatas T Conference contribution Monte-carlo simulation of the effective lunar aperture for detection of ultra-high energy neutrinos with LOFAR (2023) Krampah GK, Buitink S, Bray JD, Corstanje A, Desmet M, Falcke H, Hare BM, et al. Journal article Determinants of exposure to acrylamide in European children and adults based on urinary biomarkers: results from the “European Human Biomonitoring Initiative” HBM4EU participating studies (2023) F. Fernández S, Poteser M, Govarts E, Pardo O, Coscollà C, Schettgen T, Vogel N, et al. Journal article Shared metadata for data-centric materials science (2023) Ghiringhelli LM, Baldauf C, Bereau T, Brockhauser S, Carbogno C, Chamanara J, Cozzini S, et al. Journal article Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension (2023) D'Agostino MA, Carron P, Gaillez C, Conaghan PG, Naredo E, López-Rdz A, Šenolt L, et al. Journal article Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant (2023) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Journal article